Amylyx Pharmaceuticals, Inc.
AMLX
Rank in Stocks
#4497
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Share Price
$27.25
Last synced: 2026-10-19
Market Cap
$3.42B
Change (1 day)
3.45%
Change (1 year)
77.29%
Country
US
Trade Amylyx Pharmaceuticals, Inc. (AMLX)
Category
Healthcare
P/B ratio for Amylyx Pharmaceuticals, Inc. (AMLX)
P/B ratio as of October 2026 TTM: 12.57
According to Amylyx Pharmaceuticals, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 12.57. At the end of 2023 the company had a P/B ratio of 2.28.
P/B ratio history for Amylyx Pharmaceuticals, Inc. from 2019 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 12.57 | 705.59% |
| 2024 | 1.56 | -31.54% |
| 2023 | 2.28 | -68.35% |
| 2022 | 7.22 | -204.32% |
| 2021 | -6.92 | -54.77% |
| 2020 | -15.29 | -62.00% |
| 2019 | -40.24 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | -50.26% |
US
|
|
| 13.2547 | 5.47% |
US
|
|
| 4.208 | -66.52% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -50.81% |
NL
|
